History - Impax Laboratories, Inc.
Impax Laboratories is an integrated specialty pharmaceutical company focused on developing, manufacturing and marketing generic and specialty pharmaceutical products. Impax To Present Data On Rytary® Carbidopa And Levodopa Extended-Release Capsules, Zomig® Zolmitriptan Nasal Spray And Investigational Drug IPX203 At The 2017. Impax Receives Positive CHMP Opinion for NUMIENT™ Levodopa and Carbidopa Modified-Release
Impax Receives Positive CHMP Opinion for NUMIENT™ Levodopa and.
IMPAX Laboratories is developing a proprietary extended-release capsule formulation of levodopa/carbidopa IPX 066 for the symptomatic treatment of early-stage. Impax Laboratories is a technology-based specialty pharmaceutical company. A leader in the development, manufacturing and marketing of specialty prescription.
Rytary carbidopa and levodopa FDA Approval History -
FDA application and approval History for Rytary carbidopa and levodopa supplied by Impax Laboratories, Inc. HAYWARD, Calif.--BUSINESS WIRE-- Impax Pharmaceuticals, a division of Impax Laboratories, Inc. NASDAQ IPXL, announced today that the U. S. Food and Drug.